Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 plus CAPOX or apatinib in first-line advanced GC/GEJ
CTR20180318Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in gastric cancer (GC), esophagogastric junction cancer, sponsored by Hengrui Therapeutics. Started Mar 2018; status: completed.
02
Drugs
camrelizumab
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on CTR20180318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180318.